p53 and retinoblastoma pathways in bladder cancer.
A majority of the aggressive, invasive bladder carcinomas have alterations in the p53 and retinoblastoma genes and pathways. Examination of the alterations in the molecules in these pathways that regulate the cell cycle and their effects on the prognosis of bladder cancer are areas of active research. While defects in the p53-Mdm2-p14 axis have been implicated in urothelial cancer, perturbations in the cyclin-dependent kinases and their inhibitors have also been extensively studied in this context. Genetic alterations of the retinoblastoma gene and aberrant post-translational modifications of its protein have also been incriminated in invasive bladder cancer. This article reviews the individual prognostic roles of alterations in these molecules in the context of bladder cancer. Additionally, we review findings from recent studies that are attempting to analyze these markers in combination in an effort to construct molecular panels that can serve as more robust outcome predictors. More importantly, alterations in these molecules are now becoming enticing targets for novel therapeutics. We also review some of these agents that can restore the tumor cells' altered homeostatic mechanisms, thereby having potential in transitional cell carcinoma therapy. Future management of bladder cancer will employ validated marker panels for outcome prediction, and novel genetic and pharmacologic agents that will be able to target molecular alterations in individual tumors based on their respective profiles.
Mitra
Anirban P
AP
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
Birkhahn
Marc
M
Cote
Richard J
RJ
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002277:Carcinoma / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D018797:Cell Cycle Proteins / Q000235:genetics / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006801:Humans; D009154:Mutation; D011379:Prognosis; D040901:Proteomics; D016160:Retinoblastoma Protein / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000502:physiology*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53
Nat Med. 2002 Mar;8(3):282-8
11875500
Cell. 1979 May;17(1):43-52
222475
Science. 1996 May 10;272(5263):877-80
8629023
Eur Urol. 2006 Jul;50(1):76-82
16413663
Cancer Res. 2005 Feb 15;65(4):1150-7
15734997
Oncogene. 1991 Dec;6(12):2305-9
1766677
Clin Cancer Res. 1998 Apr;4(4):829-34
9563875
Natl Med J India. 2005 Nov-Dec;18(6):304-12
16483031
J Urol. 2002 May;167(5):2001-6
11956427
Hum Pathol. 2006 Dec;37(12):1568-76
16949911
Nature. 1996 Jun 20;381(6584):713-6
8649519
Oncogene. 2005 May 12;24(21):3484-91
15735745
Clin Genitourin Cancer. 2006 Jun;5(1):67-77
16859582
J Clin Oncol. 2006 Dec 10;24(35):5552-64
17158541
Science. 1989 Feb 17;243(4893):937-40
2521957
J Clin Oncol. 2004 Oct 15;22(20):4165-73
15483027
Br J Cancer. 2001 Jan;84(2):270-5
11161387
Vet Pathol. 1998 Nov;35(6):461-78
9823588
Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4
221923
Cancer Res. 1994 Feb 1;54(3):784-8
8306342
Carcinogenesis. 2007 Sep;28(9):1859-66
17434927
Cancer Res. 1998 Mar 15;58(6):1090-4
9515785
Clin Cancer Res. 2003 Jan;9(1):235-42
12538475
Cell. 1992 Sep 18;70(6):923-35
1356076
J Clin Oncol. 2004 Mar 15;22(6):1014-24
14981102
J Clin Oncol. 2003 Jun 15;21(12):2247-53
12805322
Mol Cell Biol. 1995 Aug;15(8):4215-24
7623816
BMC Cancer. 2006 Jun 16;6:159
16780590
J Urol. 2005 Feb;173(2):604-9
15643273
Nature. 1979 Mar 15;278(5701):261-3
218111
Urology. 2000 Oct 1;56(4):689-95
11018640
J Clin Oncol. 2001 Feb 1;19(3):666-75
11157016
Br J Cancer. 2005 Nov 14;93(10):1182-90
16265353
Cancer Res. 2003 Dec 1;63(23):8108-12
14678961
Urol Oncol. 2003 Nov-Dec;21(6):456-62
14693272
Semin Oncol. 1978 Mar;5(1):57-60
635597
Cell. 1991 Jun 14;65(6):1053-61
1828392
BJU Int. 2005 Jul;96(1):7-12
15963111
Cell. 1994 Jul 15;78(1):59-66
8033212
Clin Cancer Res. 2002 Jan;8(1):171-9
11801555
Nature. 1997 Jan 9;385(6612):123-5
8990112
Cancer Res. 1992 Mar 15;52(6):1393-8
1540947
Am J Pathol. 1993 Nov;143(5):1389-97
7901994
Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5257-61
2052605
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95
14508085
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
5279523
Urol Oncol. 2000 Sep 1;5(5):191-203
10973707
Cancer Res. 2003 Feb 15;63(4):760-5
12591722
N Engl J Med. 1994 Nov 10;331(19):1259-64
7935683
Br J Cancer. 2004 Aug 2;91(3):552-7
15226775
J Urol. 1996 Feb;155(2):753-6
8558719
Cell. 1989 Jun 30;57(7):1083-93
2525423
Proc Natl Acad Sci U S A. 1990 Apr;87(7):2775-9
2181449
J Clin Oncol. 2002 Feb 15;20(4):957-65
11844817
J Natl Cancer Inst. 1992 Aug 19;84(16):1251-6
1640484
Genes Dev. 1993 Jul;7(7A):1126-32
8319905
Cell. 1993 Nov 19;75(4):817-25
8242752
J Urol. 2001 Oct;166(4):1291-5
11547060
Oncogene. 2002 Apr 11;21(16):2476-83
11971182
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5941-6
8650198
J Natl Cancer Inst. 1992 Aug 19;84(16):1256-61
1640485
Diagn Mol Pathol. 1993 Mar;2(1):4-13
7904525
Cancer Res. 1999 Jul 1;59(13):3245-50
10397272
Cancer Res. 1996 May 15;56(10):2245-9
8625292
Br J Cancer. 2001 May 4;84(9):1242-51
11336477
Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S67-83
12850529
Cancer Res. 1990 Nov 1;50(21):7081-3
2208176
Oncogene. 2003 Sep 29;22(42):6609-20
14528286
Cancer J Sci Am. 1999 Jan-Feb;5(1):2-15
10188054
Oncogene. 2001 Apr 12;20(16):1973-80
11360181
Am J Pathol. 1999 Jul;155(1):105-13
10393843
World J Urol. 2000 Apr;18(2):148-51
10854151
J Pathol. 2004 Jul;203(3):762-70
15221935
J Natl Cancer Inst. 1998 Jul 15;90(14):1072-9
9672255
Mod Pathol. 2007 Apr;20(4):445-59
17384651
Science. 1989 Apr 14;244(4901):217-21
2649981
Br J Cancer. 1995 Apr;71(4):831-5
7710951
Int J Urol. 2000 Oct;7(10):366-72
11144504
J Natl Cancer Inst. 1998 Jun 17;90(12):916-20
9637141
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
J Clin Oncol. 2004 Mar 15;22(6):1007-13
14981105